Clinical trial
Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine…
NCT00345878 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00345878 |
|---|---|
| Title | Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years |
| Official title | Phase 3, Open, Age-stratified Study to Assess Immunogenicity and Safety of GSK Biologicals' HPV-16/18 Vaccine Administered Intramuscularly According to 3-dose Schedule (0,1,6 Months) in Healthy Female Subjects Aged 15 - 55 Years and Long Term Follow-up |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Papillomavirus |
| Intervention type | Biological |
| Interventions | Placebo, HPV-16/18 L1 VLP AS04 (Cervarix TM) |
| Enrollment | 271 |
| Start date | Sep 25, 2006 |
| Primary completion | Dec 21, 2007 |
| Completion | Dec 21, 2007 |
| First posted | Jun 29, 2006 |
| Last update posted | Jul 20, 2018 |
| Countries | Malaysia |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: